Slide 1: Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases
Nasdaq: SKYE May 2026 Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases
Slide 2: Disclaimer and Important Information for Investors
© 2026 Skye Bioscience, Inc. Disclaimer and Important Information for Investors This presentation (“Presentation”) has been prepared solely for general information purposes by or on behalf of Skye Bioscience, Inc. (together with its subsidiaries and affiliates, “Skye”). Any discussion of the potenti
Slide 3: Executive Summary
© 2026 Skye Bioscience, Inc. Executive Summary Nimacimab Semaglutide CBeyond data established potential path for All drugs are investigational and subject to regulatory approval. combination strategy with Additive Improved Favorable existing incretin therapies Weight Loss Durability of Tolerability
Slide 4: What has Objectively Changed in the CB1 Field
What has Objectively Changed in the CB1 Field © 2026 Skye Bioscience, Inc. Since launching nimacimab in obesity, Skye has delivered a series of field-firsts for peripheral CB1 1 FIELD FIRST 2 CLINICAL FIRST 3 COMBINATION FIRST First human obesity First-in-class modality First CB1 + GLP-1 dataset pro
Slide 5: CBeyond: Three Primary Learnings
© 2026 Skye Bioscience, Inc. CBeyond: Three Primary Learnings Meaningful combo efficacy, clean safety, and a clear dosing path LEARNING 1 LEARNING 2 LEARNING 3 Meaningful combination signal Clean safety and tolerability Solvable development variable +3.0% 0 200 mg incremental weight loss vs semaglut
Slide 6: Investment Thesis – GLP-1s Are Facing a Pricing Cliff
Investment Thesis – GLP-1s Are Facing a Pricing Cliff © 2026 Skye Bioscience, Inc. Nimacimab: complementary, not competitive – potential scalable add-on to enhance incretin therapy $400/month • Semaglutide patents due to expire in 10 countries globally in 2026 2026 (Canada, India, Brazil, etc.). • U
Slide 7: Investment Thesis – Nimacimab Target Product Profile
Investment Thesis – Nimacimab Target Product Profile © 2026 Skye Bioscience, Inc. Nimacimab: complementary, not competitive – potential scalable add-on to enhance incretin therapy Obesity is becoming a chronic, multi-line treatment market — and a meaningful proportion of patients already exposed to
Slide 8: Nimacimab
Nimacimab A Highly Peripherally-restricted CB1-inhibiting Antibody that Stands Apart from Small– molecule CB1 Inhibitors
Slide 9: Peripheral CB1 Signaling: Metabolic-focused Targets
A blue and green gradient background AI-generated content may be incorrect. Peripheral CB1 Signaling: Metabolic-focused Targets © 2026 Skye Bioscience, Inc. Active CB1 engagement promotes inflammation, fibrosis, and metabolic dysfunction; blocking peripheral CB1 can potentially reverse negatively-tr
Slide 10: Nimacimab: Peripherally-restricted CB1-inhibiting Antibody
A blue and purple background with white text AI-generated content may be incorrect. Nimacimab: Peripherally-restricted CB1-inhibiting Antibody © 2026 Skye Bioscience, Inc. • Stable antibody with half-life of 18-21 days (potential Q2W or monthly dosing) Long Half-life • Single mutation in the hinge r
Slide 11: Nimacimab’s Potential Differentiation from Small Molecule CB1 Inhibitors
Nimacimab’s Potential Differentiation from Small © 2026 Skye Bioscience, Inc. Molecule CB1 Inhibitors Peripheral Restriction Negative Allosteric Modulator 2-AG or AEA All drugs are investigational and subject to regulatory approval. Unlike small molecules currently in Significantly less brain develo
Slide 12: Nimacimab Potency Similar to Small Molecule Inhibitors
© 2026 Skye Bioscience, Inc. Nimacimab Potency Similar to Small Molecule Inhibitors Based on both cAMP and b-arrestin assays cAMP-based Assay -Arrestin-based Assay All drugs are investigational and subject to regulatory approval. CB1 Inhibitor IC50 (nM) CB1 Inhibitor IC50 (nM) Nimacimab 4.96 Nimaci
Slide 13: Non-competitive CB1 Inhibition
Non-competitive CB1 Inhibition: Differentiation of © 2026 Skye Bioscience, Inc. Nimacimab’s Allosteric Modulation Monlunabant Nimacimab 2-AG or AEA 2-AG or AEA Monlunabant Nimacimab non- competes with competitively binds AEA/2-AG for allosteric site; binding to the AEA/2-AG binds the orthosteric sit
Slide 14: Four Mechanistic Pillars of Nimacimab
A cover of a book AI-generated content may be incorrect. Four Mechanistic Pillars of Nimacimab © 2026 Skye Bioscience, Inc. 01 02 03 04 Peripheral Modulation Improvement Enhanced Lipid Reduction of Obesity- of Appetite Regulating and Restoration of Metabolism Induced Inflammation Hormones Glycemic C
Slide 15: Nimacimab Modulates Appetite-regulating Hormones
© 2026 Skye Bioscience, Inc. Nimacimab Modulates Appetite-regulating Hormones and Reduces Cumulative Food Intake Ghrelin Leptin Cumulative Food Intake All drugs are investigational and subject to regulatory approval. Serum was collected on day 35, and Ghrelin, and Leptin levels were determined with
Slide 16: Nimacimab Improves Glycemic Control
© 2026 Skye Bioscience, Inc. Nimacimab Improves Glycemic Control A Fasting Glucose B Fasting Insulin C HOMA-IR All drugs are investigational and subject to regulatory approval. D Glucose Tolerance Test E GTT AUC F Insulin Tolerance Test On day 25 of treatment, animals were fasted for 4 h and glucose
Slide 17: Nimacimab Increases Energy Expenditure
Nimacimab Increases Energy Expenditure © 2026 Skye Bioscience, Inc. DIO mice (n=6) placed in PhenoMaster metabolic cages were dosed nimacimab 240 mg/kg or vehicle (control DIO) Q3D for 14 days. O 2 consumption, CO2 production, food/water intake, and activity were recorded. Nimacimab treatment result
Slide 18: Nimacimab Modulates Lipid Metabolism
© 2026 Skye Bioscience, Inc. Nimacimab Modulates Lipid Metabolism Hepatic Steatosis Grading % of Steatosis Area in Liver Serum Cholesterol A B C All drugs are investigational and subject to regulatory approval. D H&E Control Diet Vehicle Nimacimab 24 mg/kg Nimacimab 75 mg/kg Semaglutide 0.04 mg/kg (
Slide 19: Nimacimab Reduces Obesity-induced Inflammation
© 2026 Skye Bioscience, Inc. Nimacimab Reduces Obesity-induced Inflammation Adipocyte Macrophages Hepatic Macrophages Hepatic Fibrosis A B C All drugs are investigational and subject to regulatory approval. D iWAT F4/80 Control Nimacimab Nimacimab Semaglutide Diet Vehicle 24 mg/kg 75 mg/kg 0.04 mg/k
Slide 20: Development and Implementation of a Human CB1 DIO Mice Model
Development and Implementation of a Human CB1 DIO Mice © 2026 Skye Bioscience, Inc. Model to Demonstrate a Dose-response with Nimacimab A hCB1 Genotyping C Dose Curves from Multiple Diet-Induced Obese Studies hCB1 C57BL/6 wt C57BL/6 Homo Het wt Mouse CB1 Human CB1 In hCB1 transgenic mice, the human
Slide 21: Nimacimab Significantly Enhances Weight Loss
© 2026 Skye Bioscience, Inc. Nimacimab Significantly Enhances Weight Loss as Monotherapy or Combined with Low-Dose Tirzepatide A Absolute Weight B Vehicle-adjusted % Weight Loss The daily average change in body weight from day 1 of treatment from the vehicle group was subtracted from the individual
Slide 22: Intermediate Reduction in Food Intake with Nimacimab
© 2026 Skye Bioscience, Inc. Intermediate Reduction in Food Intake with Nimacimab Combo improves WL but does not reduce calories, suggesting alternative MOAs Daily Food Intake Nimacimab Pair-fed DIO Mice All drugs are investigational and subject to regulatory approval. Cumulative Food Intake For cum
Slide 23: Active Dose of Nimacimab Significantly Enhances Combination with Semaglutide
Active Dose of Nimacimab Significantly Enhances © 2026 Skye Bioscience, Inc. Combination with Semaglutide Clinical Equivalents ~CBeyond 200mg ~Proposed 600mg ~CBeyond 200mg Combo ~Proposed 600mg Combo The control DIO’s daily average change in body weight was subtracted from each animal's individual
Slide 24: Nimacimab Drives Durable Weight Loss with Minimal Rebound
Nimacimab Drives Durable Weight Loss with Minimal © 2026 Skye Bioscience, Inc. Rebound Compared to Tirzepatide Treatment Phase A Discontinuation Phase B ∆29.7% tirzepatide ‘rebound’ ∆7.4% nimacimab ‘rebound’ Data are expressed as mean ± SEM. n=8 per group
Slide 25: Switching to Nimacimab Treatment Limits Rebound
© 2026 Skye Bioscience, Inc. Switching to Nimacimab Treatment Limits Rebound and Shows Significant Potential as Maintenance Therapy Discontinuation Phase A or switch to Nima Phase B ∆29.7% tirzepatide ‘rebound’ ∆12.8% nimacimab ‘switch’ Data are expressed as mean ± SEM.N=8 per group.
Slide 26: Switching to Nimacimab Limits Rebound
Switching to Nimacimab Limits Rebound and Continues © 2026 Skye Bioscience, Inc. to Highlight Potential as Maintenance Therapy Vehicle-adjusted % Weight Loss Vehicle-adjusted % Weight Loss Discontinue or Phase A Discontinuation Phase B Phase A Switch to Nima Phase B Data are expressed as mean ± SE
Slide 27: Review of Interim Extension Study: 52-Week Combination Data
Review of Interim Extension Study: 52-Week Combination Data
Slide 28: CBeyond Phase 2a Clinical Trial Design for Proof of Concept
CBeyond Phase 2a Clinical Trial Design for Proof of Concept © 2026 Skye Bioscience, Inc. Monotherapy and combination arms: weight loss, safety/tolerability, body composition, biomarkers SubQ Nimacimab 200 mg QW Sub Q Nimacimab 300 mg QW Randomized Placebo QW 2:2:1:1 All drugs are investigational and
Slide 29: Nimacimab + Semaglutide Performed Better Than Semaglutide Alone
© 2026 Skye Bioscience, Inc. Nimacimab + Semaglutide Performed Better Than Semaglutide Alone Change in Body Weight • Combination of nimacimab + semaglutide resulted in a 30% increase All drugs are investigational and subject to regulatory approval. compared to semaglutide alone in CBeyond at 26 week
Slide 30: Combination Subjects Similar between Extension and Follow-up Groups
© 2026 Skye Bioscience, Inc. Combination Subjects Similar between Extension and Follow-up Groups Change in Body Weight • 10 subjects on active combination (nimacimab + semaglutide) rolled over to extension • 11 subjects on the nimacimab + semaglutide All drugs are investigational and subject to regu
Slide 31: Combination Group Demonstrated 22.3% Weight Loss at 52-Weeks
© 2026 Skye Bioscience, Inc. Combination Group Demonstrated 22.3% Weight Loss at 52-Weeks Change in Body Weight • Following an additional 26-weeks of dosing of nimacimab + semaglutide, a further 7.9% weight loss was achieved • This represents 35% of total weight All drugs are investigational and sub
Slide 32: Semaglutide Subjects Were Different Between Extension and Follow-Up
© 2026 Skye Bioscience, Inc. Semaglutide Subjects Were Different Between Extension and Follow-Up Change in Body Weight • 9 subjects in the semaglutide alone (with placebo) arm enrolled in the extension study. • 11 subjects in the semaglutide arm went into off therapy follow • There was a marked diff
Slide 33: Semaglutide Group Demonstrated a 19.7% Weight Loss at 52-Weeks
© 2026 Skye Bioscience, Inc. Semaglutide Group Demonstrated a 19.7% Weight Loss at 52-Weeks Change in Body Weight • Following an additional 26-weeks of dosing of semaglutide + placebo, a further 5.8% weight loss was achieved. • The additional 5.8% represents 29.4% of All drugs are investigational an
Slide 34: Nimacimab Converts Patients to “Super Responders”
© 2026 Skye Bioscience, Inc. Nimacimab Converts Patients to “Super Responders” Change in Body Weight • Unusually high frequency of sema ‘super-responders’ makes it challenging to differentiate the combo effect All drugs are investigational and subject to regulatory approval. • Sema discontinuation g
Slide 35: Nimacimab Reduces Weight Regain Off-Therapy
© 2026 Skye Bioscience, Inc. Nimacimab Reduces Weight Regain Off-Therapy Follow-Up for 13 Weeks after the Last Dose DIO Study All drugs are investigational and subject to regulatory approval. 37.3% (2.8kg) 17.8% (2.3kg) Inclusion criteria: patients must have completed at least 75% of treatment and h
Slide 36: Typical Semaglutide Rebound Profile
© 2026 Skye Bioscience, Inc. Typical Semaglutide Rebound Profile All drugs are investigational and subject to regulatory approval. Wilding et al., 2022. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension 36
Slide 37: Differentiated Body Composition Through 13-Week Follow-Up
© 2026 Skye Bioscience, Inc. Differentiated Body Composition Through 13-Week Follow-Up Combo Group Combo Group Gains Lean to Fat Mass Maintains Fat Mass Lean Mass During Ratio Improves During Follow-Up Follow-Up Period Compared to Sema Period Alone All drugs are investigational and subject to regula
Slide 38: Summary and Conclusions
© 2026 Skye Bioscience, Inc. Summary and Conclusions • Weight loss of 22.3% with no evidence of plateau is comparable to other combination therapies at 52 weeks. • Combination of nimacimab + semaglutide continued to demonstrate safe and tolerable profile at tested doses, similar to semaglutide- alon
Slide 39: What We Learned From Dosing Strategy and Rationale
What We Learned From Dosing Strategy and Rationale
Slide 40: Initial Rationale for CBeyond Dosing
© 2026 Skye Bioscience, Inc. Initial Rationale for CBeyond Dosing • Before pharmacodynamic data (clinical weight loss or DIO model), Skye developed clinical PK models (Ph1 data) to understand dosing options • IC90 (serum) was used as a surrogate for target engagement • Similar IC90 at Cmax, ss with
Slide 41: Nimacimab Biodistribution in Lean and Obese Mice
© 2026 Skye Bioscience, Inc. Nimacimab Biodistribution in Lean and Obese Mice All drugs are investigational and subject to regulatory approval. Human IgG ELISA kit (Ray Biotech, catalog# ELH-IGG) was used to detect 41 nimacimab in tissue homogenates. Results are reported as ng of nimacimab/mg 2-way
Slide 42: Nimacimab Tissue Biodistribution in Lean and Obese Mice
© 2026 Skye Bioscience, Inc. Nimacimab Tissue Biodistribution in Lean and Obese Mice All drugs are investigational and subject to regulatory approval. Human IgG ELISA kit (Ray Biotech, catalog# ELH-IGG) was used to detect 42 nimacimab in tissue homogenates. Results are reported as ng of nimacimab/mg
Slide 43: Beyond the Serum: CB1 Inhibition in Peripheral Tissues
© 2026 Skye Bioscience, Inc. Beyond the Serum: CB1 Inhibition in Peripheral Tissues Small molecule vs antibody-based CB1 inhibitors demonstrate differential distribution in peripheral tissues Small molecule Antibody “S-MRI-1867 exhibited high exposure “Tissue distribution of Antibody distribution in
Slide 44: Compartmental Analysis: Activity Associated with CB1 Inhibition
© 2026 Skye Bioscience, Inc. Compartmental Analysis: Activity Associated with CB1 Inhibition in Peripheral Tissue Blood Adipose Brain Dose Curves from Multiple DIO Studies Input dose nimacimab concentration (relative to IC90) All drugs are investigational and subject to regulatory approval. 200 mg 2
Slide 45: CBeyond Dosing did not Achieve Significant Concentrations in the Serum
© 2026 Skye Bioscience, Inc. 200 mg QW CBeyond Dosing did not Achieve Significant Concentrations in the Serum • While 200 mg QW achieved median serum exposures of at least 7x over IC90; however, this dose proved to be sub- 200 mg QW Dosing Simulation optimal. All drugs are investigational and subjec
Slide 46: How Much Higher Can Nimacimab Be Safely Dosed?
© 2026 Skye Bioscience, Inc. How Much Higher Can Nimacimab Be Safely Dosed? Nimacimab NOAEL based on 26-week NHP study is 75mg/kg Phase 2b Simulations: Limiting toxicity assessment Considering the human equivalent dose (HED) from the FDA guidance: All drugs are investigational and subject to regulat
Slide 47: Modeling NHP Toxicity Study Provides Guidance for Potential Dosing Regimens
© 2026 Skye Bioscience, Inc. Modeling NHP Toxicity Study Provides Guidance for Potential Nimacimab Dosing Regimens • Skye has conducted two non-human primate toxicology studies both establishing 75mg/kg as NOAEL dose. 1. 26-Week Subcutaneous Dosing (N=9) 2. 4-Week IV Dosing (N=10) Cmax Weekly AUC Al
Slide 48: Higher Dosing Well Below NOAEL Dose
© 2026 Skye Bioscience, Inc. Higher Dosing Well Below NOAEL Dose • In order to achieve at least 200 ug/mL in the serum, we simulated 600 mg QW and 1200 mg QW 600 mg QW 1200 mg QW Exposure vs. NOAEL All drugs are investigational and subject to regulatory approval. Concentration (ug/mL) Dose 1200 mg N
Slide 49: Monlunabant’s Dose Dependent Increase in Brain
© 2026 Skye Bioscience, Inc. Monlunabant’s Dose Dependent Increase in Brain Leads to Dose Dependent Increase in Neuropsychiatric Adverse Events Monlunabant - Brain Exposure 80 Monlunabant 50 mg Monlunabant 20 mg • Monlunbant’s Phase 2a 16-week data Monlunabant 10 mg demonstrated a dose dependent inc
Slide 50: Nimacimab has Wide Safety Margin in the Brain
© 2026 Skye Bioscience, Inc. Nimacimab has Wide Safety Margin in the Brain • Modeling of brain exposure for nimacimab (antibody) shows a significantly better safety margin than monlunabant (small molecule). • Wang et al., demonstrates brain (CSF) to serum concentration ratios are between 0.1%-0.2% f
Slide 51: Clinical Strategy: CBeyond Expansion Study
Clinical Strategy CBeyond Expansion Study
Slide 52: CBeyond Expansion Study / Part C / IV Dosing
CBeyond Expansion Study / Part C / IV Dosing © 2026 Skye Bioscience, Inc. Cohort 2 Randomized 3:1 to either • Nimacimab 600 mg, QW, IV (n=6), equivalent to ~1000 mg SC • Matched placebo, QW, IV (n=2) Safe to Proceed to Cohort 2 following Cohort Review All drugs are investigational and subject to reg
Slide 53: IV Dosing for CBeyond Part C
© 2026 Skye Bioscience, Inc. IV Dosing for CBeyond Part C 400 mg IV QW Time to Target Concentration and Steady State Confidential Ctrough Time to Weekly Dose >200ug/mL Steady State 400 mg IV Week 12 Week 9 All drugs are investigational and subject to regulatory approval. 600 mg IV Week 5 Week 9 600
Slide 54: Confirming Safety and High Dose Strategy
© 2026 Skye Bioscience, Inc. Confirming Safety and High Dose Strategy • The Expansion (Part C) Study will provide key data to confirm that nimacimab will not significantly penetrate the blood-brain barrier and result in neuropsychiatric side effects. All drugs are investigational and subject to regu
Slide 55: Achieving Large Volume Dose Administration with ENHANZE®
A green and white background with white text AI-generated content may be incorrect. Achieving Large Volume Dose Administration with © 2026 Skye Bioscience, Inc. ENHANZE® • Skye has established a global collaboration and Large volume injection up licensing agreement with Halozyme Therapeutics to eval
Slide 56: Target Product Profile
Target Product Profile
Slide 57: Current AOM Pipeline and Treatment Paradigm
© 2026 Skye Bioscience, Inc. Current AOM Pipeline and Treatment Paradigm Presentation and Diagnosis Initial Treatment Follow On/Maintenance Therapy Clinical GLP-1 Receptor Agonists Target Weight Loss Achieved Presentation of First Medical Contact Primary Care Obesity Physician Wegovy Zepbound Mainte
Slide 58: Novo 2020-2025 Demonstrates the Remarkable Growth of the Obesity Market
© 2026 Skye Bioscience, Inc. Novo 2020-2025 Demonstrates the Remarkable Growth of the Obesity Market Driven by Semaglutide (Wegovy®) Pre-Wegovy® Approval 3 Years Post-Wegovy® Approval © 2026 Skye Bioscience, Inc. Internal Work Product | 58 Source: Novo Nordisk 2021 and 2025 Full Year Review Presenta
Slide 59: While More Patients Are Receiving Therapy, Few Are Staying On Treatment
While More Patients Are Receiving Therapy, Few Are © 2026 Skye Bioscience, Inc. Staying On Treatment And Require Additional Options © 2026 Skye Bioscience, Inc. Internal Work Product | HOWEVER - This Has Created a True Need For Alternative Options to GLP-1s 59 Source: Novo Nordisk 2024 Full Year Rev
Slide 60: Significant Growth of Contrave and Qysmia Demonstrates Unmet Need
© 2026 Skye Bioscience, Inc. Significant Growth of Contrave and Qysmia Demonstrates Unmet Need For GLP-1 Experienced Patients Naltrexone/bupropion Phentermine/topiramate 2017 Both drugs $13M annual sales $17M annual sale commercially failed as 1L therapies Company goes bankrupt and Contrave to Since
Slide 61: Percentage of Patients Who Do Not Respond to GLP-1s
© 2026 Skye Bioscience, Inc. Percentage of Patients Who Do Not Respond to GLP-1s or May Require Additional Weight Loss “Non-Responders” “Needs More WL” Drug Study <5% WL <10% WL Semaglutide (SC) STEP-1 13.6% 30.9% Semaglutide (Oral) OASIS-4 20.8% 37.0% All drugs are investigational and subject to re
Slide 62: New Treatments, Including Orals, Will Serve to Expand GLP-1 Experienced Patients
New Treatments, Including Orals, Will Serve to Expand © 2026 Skye Bioscience, Inc. the Number of GLP-1 Experienced Patients © 2026 Skye Bioscience, Inc. Internal Work Product | “…a large proportion initiating oral semaglutide (36.1%) had no prior evidence of GLP-1-therapy use, suggesting that early
Slide 63: Crowded 1L Space with Significant Price Compression
© 2026 Skye Bioscience, Inc. Crowded 1L Space with Significant Price Compression • NuSH drugs will dominate the 1L setting, but it will become increasingly competitive with less room for profit margin. • The 2L setting has significant opportunity with few non-NuSH drugs available or being developed.
Slide 64: Nimacimab Complementary, Not Competitive to GLP-1s
© 2026 Skye Bioscience, Inc. Nimacimab Complementary, Not Competitive to GLP-1s Maintenance rationale for late comer GLP1s is to protect the patient base; nimacimab improves persistence and durability of 1L GLP1s WHY THEY DO IT WHY IT IS HARD FOR INCRETINS WHY NIMACIMAB WINS Maintenance is a rationa
Slide 65: COGS and Commercial Strategy
COGS and Commercial Strategy
Slide 66: Nimacimab COGS – Line of Site to Competitive Pricing
Nimacimab COGS – Line of Site to Competitive Pricing © 2026 Skye Bioscience, Inc. ➢ Drug Substance current productivity: 2.5 g/L titer & 40% downstream recovery ▪ Process productivity improvement development activities underway; scale-up to 12-15K L planned 600 mg 2400 mg 600 mg 2400 mg Dose QW Q4W
Slide 67: Competitive Pricing Strategy
© 2025 Skye Bioscience, Inc. Competitive Pricing Strategy • Current pricing of obesity drugs have a 54-67% discount to the wholesale list price (i.e. WAC Price). • Average patient out-of-pocket costs range from $98 to $500 per month. • Pricing of nimacimab at an annual WAC price of $8,220 with a 60%
Slide 68: Global Patent Expiration of Semaglutide is a Commercial Opportunity for Nimacimab
© 2026 Skye Bioscience, Inc. Global Patent Expiration of Semaglutide is a Commercial Opportunity for Nimacimab • Patents for semaglutide are due to expire in several countries from April 2026 – examples include India, China, Canada, Brazil and Turkey - enabling the development and distribution of ge
Slide 69: Financial Overview and Team
Financial Overview and Team
Slide 70: Selected Financial Figures & Metrics
Selected Financial Figures & Metrics © 2026 Skye Bioscience, Inc. Stock Information • $107M in equity capital raised since Listed: Nasdaq SKYE August 2023 (no new equity financing issuances since March Stock Price1 $0.88 2024 PIPE) All drugs are investigational and subject to regulatory approval. •
Slide 71: Leadership
Leadership Contributed to commercialization of 40+ drugs/diagnostics, led high-value strategic transactions, and co-founded multiple companies Executive Management Board of Directors Punit Dhillon Tu Diep, MSc Paul Grayson Annalisa Jenkins, Deborah Charych, PhD President & CEO Chief Operating Office
Slide 72: THANK YOU
THANK YOU 11250 El Camino Real, Suite 100 San Diego, CA 92130 Please learn more or contact us at: ir@skyebioscience.com +1 (858) 410-0266 Spotlight